EGFR and lung carcinoma: MET amplification activates human epidermal growth factor3 (ERBB3)–phosphatidylinositol 3 kinase (PI3K)–protein kinase B (AKT) signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors.